Maintenance therapy with cotrimoxazole for toxoplasmic encephalitis in the era of highly active antiretroviral therapy.
To reduce the number of daily pills for improving adherence to antiretrovirals, 17 protease inhibitor-treated patients receiving toxoplasmic encephalitis (TE) standard maintenance therapy were instead given cotrimoxazole 960 mg twice daily. After a median follow-up of 31 months, one relapsed after three months, TE relapse incidence = 2.1 cases per 100 patient-years (95% confidence interval, 0.05-11.3). This strategy could be useful for patients awaiting immune reconstitution which allows the interruption of TE maintenance therapy.
Duval
Xavier
X
Department of Infectious Diseases, Bichat-Claude Bernard Hospital, Paris, France.
Pajot
O
O
Le Moing
V
V
Longuet
P
P
Ecobichon
J L
JL
Mentre
F
F
Leport
C
C
Vilde
J L
JL
D000818:Animals; D019380:Anti-HIV Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology / Q000469:parasitology*; D006801:Humans; D008297:Male; D012008:Recurrence; D014122:Toxoplasma; D016781:Toxoplasmosis, Cerebral / Q000517:prevention & control* / Q000821:virology; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use*; D019562:Viral Load
D019380:Anti-HIV Agents; D000890:Anti-Infective Agents; D015662:Trimethoprim, Sulfamethoxazole Drug Combination